{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:44:31Z","timestamp":1767840271505,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIHR Southampton Biomedical Research Centre","award":["IS-BRC-1215-20004"],"award-info":[{"award-number":["IS-BRC-1215-20004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rapid development of an effective vaccine for SARSCoV2 is a global priority. A controlled human infection model (CHIM) would accelerate the efficacy assessment of candidate vaccines. This strategy would require deliberate exposure of volunteers to SARSCoV2 with no currently available treatment and a small but definite risk of serious illness or death. This raises complex questions about the social and ethical acceptability of risk to individuals, given the potential benefit to the wider population, and as such, a study cannot be done without public involvement. We conducted a structured public consultation with 57 individuals aged 20\u201340\u2009years to understand public attitudes to a CHIM, and pre-requisites for enrolment. The overall response to this strategy was positive, and many would volunteer altruistically. Carefully controlled infection is viewed as safer than natural exposure to wild virus. The prolonged social isolation required for the proposed CHIM is considered an obstacle but not insurmountable, with reasonable compensation and supportive care. Given the significant level of public interest, a CHIM should be done as open science with regular, controlled dissemination of information into the public domain. Importantly, there was a strong view that the final decision whether to conduct a CHIM should be in the hands of qualified and experienced clinician-scientists and the authorities.<\/jats:p>","DOI":"10.1186\/s12916-020-01670-2","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T09:03:32Z","timestamp":1594112612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Exploring the acceptability of controlled human infection with SARSCoV2\u2014a public consultation"],"prefix":"10.1186","volume":"18","author":[{"given":"D.","family":"Gbesemete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. T.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-6728","authenticated-orcid":false,"given":"R. C.","family":"Read","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"1670_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1473-3099(12)70292-X","volume":"12","author":"AJ Pollard","year":"2012","unstructured":"Pollard AJ, Savulescu J, Oxford J, Hill AV, Levine MM, Lewis DJ, et al. Human microbial challenge: the ultimate animal model. Lancet Infect Dis. 2012;12:903\u20135.","journal-title":"Lancet Infect Dis"},{"key":"1670_CR2","volume-title":"Human challenge trials for vaccine development: regulatory considerations. WHO Technical Report Series, No. 1004","author":"WHO Expert Committee on Biological Standardization","year":"2017","unstructured":"WHO Expert Committee on Biological Standardization. Human challenge trials for vaccine development: regulatory considerations. WHO Technical Report Series, No. 1004, 2017. Accessed May 2020. Available from: https:\/\/www.who.int\/biologicals\/expert_committee\/WHO_TRS_1004_web_Annex_10.pdf?ua=1."},{"key":"1670_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"T Thanh Le","year":"2020","unstructured":"Thanh Le T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"1670_CR4","doi-asserted-by":"publisher","first-page":"e57755","DOI":"10.1371\/journal.pone.0057755","volume":"8","author":"ES Pronker","year":"2013","unstructured":"Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One. 2013;8:e57755.","journal-title":"PLoS One"},{"key":"1670_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583\u20139.","journal-title":"Immunity."},{"key":"1670_CR6","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/infdis\/jiaa152","volume":"221","author":"N Eyal","year":"2020","unstructured":"Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis. 2020;221:1752\u20136.","journal-title":"J Infect Dis"},{"key":"1670_CR7","volume-title":"Key criteria for the ethical acceptability of COVID-19 human challenge studies","author":"World Health Organisation","year":"2020","unstructured":"World Health Organisation. Key criteria for the ethical acceptability of COVID-19 human challenge studies. 2020. Accessed May 2020. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331976\/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1."},{"key":"1670_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri2902","volume":"11","author":"RW Sauerwein","year":"2011","unstructured":"Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11:57\u201364.","journal-title":"Nat Rev Immunol"},{"key":"1670_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1164\/rccm.201503-0542OC","volume":"192","author":"AM Collins","year":"2015","unstructured":"Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, et al. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. Am J Respir Crit Care Med. 2015;192:853\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1670_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/cid\/ciy670","volume":"68","author":"MM Gibani","year":"2019","unstructured":"Gibani MM, Voysey M, Jin C, Jones C, Thomaides-Brears H, Jones E, et al. The impact of vaccination and prior exposure on stool shedding of Salmonella Typhi and Salmonella Paratyphi in 6 controlled human infection studies. Clin Infect Dis. 2019;68:1265\u201373.","journal-title":"Clin Infect Dis"},{"key":"1670_CR11","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/cid\/ciw145","volume":"62","author":"WH Chen","year":"2016","unstructured":"Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016;62:1329\u201335.","journal-title":"Clin Infect Dis"},{"key":"1670_CR12","first-page":"3","volume":"1","author":"DT Shirley","year":"2011","unstructured":"Shirley DT, McArthur MA. The utility of human challenge studies in vaccine development: lessons learned from cholera. Vaccine (Auckl). 2011;1:3\u201313.","journal-title":"Vaccine (Auckl)"},{"key":"1670_CR13","volume-title":"Microbial challenge studies of human volunteers","author":"Academy of Medical Sciences","year":"2005","unstructured":"Academy of Medical Sciences (2005) Microbial challenge studies of human volunteers. Available from: wwwacmedsciacuk\/policy\/policy\/microbial-challenge-studies Accessed Apr 2020."},{"key":"1670_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.micinf.2020.02.002","volume":"22","author":"JY Li","year":"2020","unstructured":"Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 2020;22:80\u20135.","journal-title":"Microbes Infect"},{"key":"1670_CR15","doi-asserted-by":"crossref","unstructured":"Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med. 2020;9:967.","DOI":"10.3390\/jcm9040967"},{"key":"1670_CR16","doi-asserted-by":"publisher","unstructured":"Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/s1473-3099(20)30243-7.","DOI":"10.1016\/s1473-3099(20)30243-7"},{"key":"1670_CR17","doi-asserted-by":"publisher","unstructured":"Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020. https:\/\/doi.org\/10.1038\/s41577-020-0308-3.","DOI":"10.1038\/s41577-020-0308-3"},{"key":"1670_CR18","doi-asserted-by":"crossref","unstructured":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12\u2013March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343\u20136.","DOI":"10.15585\/mmwr.mm6912e2"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01670-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-020-01670-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01670-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T23:21:17Z","timestamp":1625613677000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01670-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01670-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required as this was a public consultation exercise rather than research. This is stated in the HRA guidance for public involvement in the planning or design stage of research. Participants gave their consent to participate in the zoom meetings and were informed that their responses would be recorded and used anonymously. Formal consent was not taken as it is not required for public involvement in the planning or design stage of research,","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}